Review of Asprosin as new Biomarker for diagnosis different Diseases
This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer )-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifest...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Thi-Qar
2023-12-01
|
| Series: | مجلة علوم ذي قار |
| Subjects: | |
| Online Access: | https://jsci.utq.edu.iq/index.php/main/article/view/1125 |
| _version_ | 1797370934423715840 |
|---|---|
| author | safaa ehssan Baydaa Ahmed Abed Isam Noori Salman Lujain A. Ghannawi |
| author_facet | safaa ehssan Baydaa Ahmed Abed Isam Noori Salman Lujain A. Ghannawi |
| author_sort | safaa ehssan |
| collection | DOAJ |
| description |
This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer )-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifested in several cases and illnesses Asprosin hormone is newly adipokine helps the liver produce glucose. White adipose tissue secretes the novel hormone asprosin, which stimulates the release of hepatic glucose, making protein a possible target for new treatments for obesity and type 2 diabetes mellitus. Exons (65 and 66) of the gene( Fibrillin 1 (FBN1)), which was recently shown to be a new hormone released by white adipose tissues, are the final two exons that code for asprosin. However, further research is needed to fully understand how asprosin affects pancreatic beta-cells, leading to pathologically elevated cellular dysfunction and inflammation. Asprosin hormone is raised in human with metabolic disease. The findings imply that asprosin hormone may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including CVDs, obesity, T2DM, cancer, hypothyroidism, and PCOS. Depleting asprosin or attenuating its activity may potentially offer a novel therapeutic option for the treatment of T2DM and obesity.
|
| first_indexed | 2024-03-08T18:11:22Z |
| format | Article |
| id | doaj.art-49e7c925decc44eeadca20295b363a7a |
| institution | Directory Open Access Journal |
| issn | 1991-8690 2709-0256 |
| language | English |
| last_indexed | 2024-03-08T18:11:22Z |
| publishDate | 2023-12-01 |
| publisher | University of Thi-Qar |
| record_format | Article |
| series | مجلة علوم ذي قار |
| spelling | doaj.art-49e7c925decc44eeadca20295b363a7a2024-01-01T04:41:02ZengUniversity of Thi-Qarمجلة علوم ذي قار1991-86902709-02562023-12-0110210.32792/utq/utjsci/v10i2.1125 Review of Asprosin as new Biomarker for diagnosis different Diseasessafaa ehssan0Baydaa Ahmed AbedIsam Noori SalmanLujain A. GhannawiNational diabetes center mustansiriyah university This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer )-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifested in several cases and illnesses Asprosin hormone is newly adipokine helps the liver produce glucose. White adipose tissue secretes the novel hormone asprosin, which stimulates the release of hepatic glucose, making protein a possible target for new treatments for obesity and type 2 diabetes mellitus. Exons (65 and 66) of the gene( Fibrillin 1 (FBN1)), which was recently shown to be a new hormone released by white adipose tissues, are the final two exons that code for asprosin. However, further research is needed to fully understand how asprosin affects pancreatic beta-cells, leading to pathologically elevated cellular dysfunction and inflammation. Asprosin hormone is raised in human with metabolic disease. The findings imply that asprosin hormone may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including CVDs, obesity, T2DM, cancer, hypothyroidism, and PCOS. Depleting asprosin or attenuating its activity may potentially offer a novel therapeutic option for the treatment of T2DM and obesity. https://jsci.utq.edu.iq/index.php/main/article/view/1125asprosinDiabetes Mellitus type2cardiovascularFBN1Obesity |
| spellingShingle | safaa ehssan Baydaa Ahmed Abed Isam Noori Salman Lujain A. Ghannawi Review of Asprosin as new Biomarker for diagnosis different Diseases مجلة علوم ذي قار asprosin Diabetes Mellitus type2 cardiovascular FBN1 Obesity |
| title | Review of Asprosin as new Biomarker for diagnosis different Diseases |
| title_full | Review of Asprosin as new Biomarker for diagnosis different Diseases |
| title_fullStr | Review of Asprosin as new Biomarker for diagnosis different Diseases |
| title_full_unstemmed | Review of Asprosin as new Biomarker for diagnosis different Diseases |
| title_short | Review of Asprosin as new Biomarker for diagnosis different Diseases |
| title_sort | review of asprosin as new biomarker for diagnosis different diseases |
| topic | asprosin Diabetes Mellitus type2 cardiovascular FBN1 Obesity |
| url | https://jsci.utq.edu.iq/index.php/main/article/view/1125 |
| work_keys_str_mv | AT safaaehssan reviewofasprosinasnewbiomarkerfordiagnosisdifferentdiseases AT baydaaahmedabed reviewofasprosinasnewbiomarkerfordiagnosisdifferentdiseases AT isamnoorisalman reviewofasprosinasnewbiomarkerfordiagnosisdifferentdiseases AT lujainaghannawi reviewofasprosinasnewbiomarkerfordiagnosisdifferentdiseases |